[go: up one dir, main page]

WO2006037984A3 - Traitement du cancer - Google Patents

Traitement du cancer Download PDF

Info

Publication number
WO2006037984A3
WO2006037984A3 PCT/GB2005/003798 GB2005003798W WO2006037984A3 WO 2006037984 A3 WO2006037984 A3 WO 2006037984A3 GB 2005003798 W GB2005003798 W GB 2005003798W WO 2006037984 A3 WO2006037984 A3 WO 2006037984A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
cell
pretumorigenic
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/003798
Other languages
English (en)
Other versions
WO2006037984A2 (fr
Inventor
Denis Alexander
Rui Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0421734A external-priority patent/GB0421734D0/en
Priority claimed from GB0422225A external-priority patent/GB0422225D0/en
Priority claimed from GB0507785A external-priority patent/GB0507785D0/en
Application filed by Babraham Institute filed Critical Babraham Institute
Publication of WO2006037984A2 publication Critical patent/WO2006037984A2/fr
Anticipated expiration legal-status Critical
Publication of WO2006037984A3 publication Critical patent/WO2006037984A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de prévention, de traitement ou d'atténuation du cancer, en particulier du cancer résistant à un traitement génotoxique. Ces méthodes consistent à augmenter le pH intracellulaire d'une cellule tumorale ou prétumorigène autrement qu'en endommageant l'ADN de la cellule.
PCT/GB2005/003798 2004-10-01 2005-09-30 Traitement du cancer Ceased WO2006037984A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0421734.5 2004-10-01
GB0421734A GB0421734D0 (en) 2004-10-01 2004-10-01 Treatment of cancer
GB0422225A GB0422225D0 (en) 2004-10-07 2004-10-07 Treatment of cancer
GB0422225.3 2004-10-07
GB0507785A GB0507785D0 (en) 2005-04-18 2005-04-18 Treatment of cancer
GB0507785.4 2005-04-18

Publications (2)

Publication Number Publication Date
WO2006037984A2 WO2006037984A2 (fr) 2006-04-13
WO2006037984A3 true WO2006037984A3 (fr) 2007-05-31

Family

ID=36142907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003798 Ceased WO2006037984A2 (fr) 2004-10-01 2005-09-30 Traitement du cancer

Country Status (1)

Country Link
WO (1) WO2006037984A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060398A1 (fr) * 1998-05-18 1999-11-25 The Rockefeller University Procedes et agents permettant de mesurer et de controler la resistance multiple aux anticancereux

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060398A1 (fr) * 1998-05-18 1999-11-25 The Rockefeller University Procedes et agents permettant de mesurer et de controler la resistance multiple aux anticancereux

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALEXANDER DENIS R: "ONCOGENIC TYROSINE KINASES, DNA REPAIR AND SURVIVAL: THE ROLE OF BCL-XL DEAMIDATION IN TRANSFORMATION AND GENOTOXIC THERAPIES", CELL CYCLE, XX, GEORGETOWN, TX, US, vol. 3, no. 5, May 2004 (2004-05-01), pages 584 - 587, XP008074428, ISSN: 1538-4101 *
CASTAING M ET AL: "DESIGNING MULTIDRUG-RESISTANCE MODULATORS CIRCUMVENTING THE REVERSE PH GRADIENT IN TUMOURS", JOURNAL OF PHARMACY AND PHARMACOLOGY, LONDON, GB, vol. 53, no. 7, July 2001 (2001-07-01), pages 1021 - 1028, XP008074423, ISSN: 0022-3573 *
COLUCCIA A M L ET AL: "Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo", BLOOD 01 APR 2004 UNITED STATES, vol. 103, no. 7, 1 April 2004 (2004-04-01), pages 2787 - 2794, XP002417981, ISSN: 0006-4971 *
DEVERMAN B E ET AL: "Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage", CELL 04 OCT 2002 UNITED STATES, vol. 111, no. 1, 4 October 2002 (2002-10-04), pages 51 - 62, XP002417976, ISSN: 0092-8674 *
JOHNSTONE R W: "Deamidation of Bcl-XL: A new twist in a genotoxic murder mystery", MOLECULAR CELL 01 OCT 2002 UNITED STATES, vol. 10, no. 4, 1 October 2002 (2002-10-01), pages 695 - 697, XP002417979, ISSN: 1097-2765 *
SIMON S ET AL: "Intracellular pH and the control of multidrug resistance", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1994 UNITED STATES, vol. 91, no. 3, 1994, pages 1128 - 1132, XP002417980, ISSN: 0027-8424 *
TAKEHARA TETSUO ET AL: "Suppression of Bcl-xL deamidation in human hepatocellular carcinomas.", CANCER RESEARCH, vol. 63, no. 12, 15 June 2003 (2003-06-15), pages 3054 - 3057, XP002417978, ISSN: 0008-5472 *
ZHAO R ET AL: "An oncogenic tyrosine kinase inhibits DNA repair and DNA-damage-induced Bcl-xL deamidation in T cell transformation", CANCER CELL 2004 UNITED STATES, vol. 5, no. 1, January 2004 (2004-01-01), pages 37 - 49, XP002417977, ISSN: 1535-6108 *

Also Published As

Publication number Publication date
WO2006037984A2 (fr) 2006-04-13

Similar Documents

Publication Publication Date Title
WO2006138511A3 (fr) Composes et procedes pour le traitement du cancer
WO2006023649A3 (fr) Traitement de la sclerose en plaques grave
WO2007076423A3 (fr) INHIBITEURS D’ACTIVITE Akt
WO2010083170A3 (fr) Stimulation cellulaire à l'aide de nanocristaux de semi-conducteurs
WO2006138275A3 (fr) Compositions et procedes de traitement et de diagnostic de cancer
WO2008089397A3 (fr) Marqueurs du cancer adrb2
WO2010088450A3 (fr) Procédés de traitement de maladies associées à la modulation de serca
WO2009030884A3 (fr) Marqueurs de tumeur à la butyrophiline mannosylatée
WO2006009765A3 (fr) Procedes d'identification et d'utilisation de composes adaptes au traitement de cellules cancereuses resistantes aux medicaments
WO2007016578A3 (fr) Formulations a base de prenylflavonoides
EP2301533A8 (fr) Analogues de la wortmannine et leur procédé d'utilisation
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2008134752A3 (fr) Méthodes et compositions pour traiter le cancer
WO2007130501A3 (fr) Polythérapie pour traiter le cancer
WO2004110245A3 (fr) Polytherapie destinee au traitement du cancer
WO2008118792A3 (fr) Lymphocytes t gamma delta et procédés de traitement de problèmes liés à l'interleukine-17
WO2007072221A3 (fr) Agents therapeutiques anticancereux utilisant un marqueur de surface
WO2010072770A3 (fr) Analogues de griséofulvine pour le traitement du cancer par inhibition de l'agrégat centrosomial
WO2006023452A3 (fr) Analogues de la cyclosporine utilises pour le traitement de troubles immunoregulateurs et de maladies respiratoires
WO2008107471A3 (fr) Conjugués d'hydroxypolymère modifié à activité destructrice de cellules tumorales
WO2005062957A3 (fr) Compositions et procedes pour la therapie combinee de maladie
WO2013003899A8 (fr) Méthodes de traitement ou de prévention d'une maladie rhumatismale
WO2011040613A8 (fr) Agent thérapeutique anti-tumoral
WO2006125815A3 (fr) Nouveau tetrahydropyridothiophenes
WO2006125813A3 (fr) Nouveau tetrahydropyridothiophenes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase